103 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
7 May 24
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
7:03am
activity, differentiated safety and efficacy profile, and its ability to address significant unmet need for patients with serious gynecological cancers … to establish azenosertib’s monotherapy activity, differentiated safety and efficacy profile; our plans to present Phase 1 azenosertib clinical data
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Apr 24
Regulation FD Disclosure
4:30pm
in development Highly Specific Agent Targeting WEE1 Monotherapy efficacy; 37% ORR and 6.5 month mPFS in heavily pretreated ovarian and USC* Excellent safety … E1+ Tumors 102,200
Azenosertib Monotherapy Results Monotherapy Anti-tumor Activity in Gynecologic Malignancies with Favorable Safety and Tolerability
S-3ASR
EX-1.2
ZNTL
Zentalis Pharmaceuticals Inc
29 Feb 24
Automatic shelf registration
5:14pm
) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety … , safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and
(v) all other local, state
S-3ASR
ZNTL
Zentalis Pharmaceuticals Inc
29 Feb 24
Automatic shelf registration
5:14pm
internal control over financial reporting and disclosure controls and procedures; the ability of our clinical trials to demonstrate safety … clinical trials; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; the potential for azenosertib
8-K
EX-99.1
h33ctf53
27 Feb 24
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
7:04am
8-K
EX-3.1
g46yr 1au549jw4
15 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:12pm
8-K
EX-99.1
vpxku56j
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.2
61le41o6 cyjrl3crf
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.1
cksbo
13 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
g8icaps3
9 Aug 23
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
ac9wk2f 9rruy
9 Aug 23
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
7:03am
8-K
EX-1.1
pyspdu2zmb5d4kf5str
15 Jun 23
Other Events
4:23pm
424B5
fjzvplhcl93hs2oypi
15 Jun 23
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.3
zl9zb2n xfd
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.1
p8ei4mhzr
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am